SCHEMBL1503221

SCHEMBL1503221

O=C(OCO)c1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.56
ALDH1A1 P00352 7/20 0.56
KDM4E B2RXH2 1/20 0.56
GAA P10253 1/20 0.56
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
NPSR1 Q6W5P4 2/20 0.55
PKM P14618 1/20 0.55
LMNA P02545 1/20 0.53
NAPRT Q6XQN6 1/20 0.53
P4HTM Q9NXG6 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
APP P05067 1/20 0.52
NPC1 O15118 1/20 0.52
THRB P10828 1/20 0.52
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
AGTR1 P30556 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27221774 0.86 L3MBTL1 (0.58) L3MBTL1ALDH1A1KDM4EGAACES2
SCHEMBL5410378 0.85 APP (0.57) L3MBTL1ALDH1A1KDM4EGAACES2
SCHEMBL30099767 0.85 L3MBTL1 (0.60) L3MBTL1ALDH1A1KDM4EGAACES2
SCHEMBL17205087 0.83 L3MBTL1 (0.55) L3MBTL1ALDH1A1KDM4EGAACES2
SCHEMBL29554609 0.83 L3MBTL1 (0.55) L3MBTL1ALDH1A1KDM4EGAACES2
Ethyl Picolinate SCHEMBL30016787 0.83 CYP1A2 (0.65) L3MBTL1ALDH1A1KDM4EGAACES2
Ethyl Picolinate SCHEMBL8661716 0.83 CYP1A2 (0.65) L3MBTL1ALDH1A1KDM4EGAACES2
Ethyl Picolinate SCHEMBL126181 0.83 CYP1A2 (0.65) L3MBTL1ALDH1A1KDM4EGAACES2
SCHEMBL2149142 0.83 NPSR1 (0.57) L3MBTL1ALDH1A1KDM4EGAACES2
SCHEMBL1818702 0.83 L3MBTL1 (0.55) L3MBTL1ALDH1A1KDM4EGAACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201925-A Macrocyclic compounds and methods of making the same 詹森生物科技公司 2024-06-14 CN claimed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP claimed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO claimed
CN-118201925-A Macrocyclic compounds and methods of making the same 詹森生物科技公司 2024-06-14 CN disclosed
US-11931348-B2 Methods of treating elevated plasma cholesterol Montréal Heart Institute (CA) 2024-03-19 US disclosed
US-20230088095-A1 METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL Montréal Heart Institute (CA) 2023-03-23 US disclosed
CN-114641554-A Method for improving electrochemiluminescence signal in bioanalytical assays 苏州安赛诊断技术有限公司 2022-06-17 CN disclosed
CN-108698047-B Branched amines in electrochemiluminescence detection 豪夫迈·罗氏有限公司 2022-04-01 CN disclosed
CN-114127059-A Macrocyclic chelants and methods of use thereof 詹森生物科技公司 2022-03-01 CN disclosed
WO-2020237374-A1 PICOLINIC ACID DERIVATIVES AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH ELEVATED CHOLESTEROL MONTREAL HEART INSTITUTE (CA) 2020-12-03 WO disclosed
EP-3687538-A1 METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL Montreal Heart Institute (CA) 2020-08-05 EP disclosed
EP-3515914-A1 NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BeiGene, Ltd. (KY) 2019-07-31 EP disclosed
WO-2018054365-A1 NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE, LTD. (KY) 2018-03-29 WO disclosed
EP-3280715-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES Beigene, Ltd. (KY) 2018-02-14 EP disclosed
WO-2016161960-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE, LTD. (KY) 2016-10-13 WO disclosed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP disclosed
EP-2200967-A2 NEW NO-DONOR ASPIRIN DERIVATIVES Nicox S.A. (FR) 2010-06-30 EP disclosed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO disclosed
WO-2009049961-A2 NEW NO-DONOR ASPIRIN DERIVATIVES NICOX S.A. (FR) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11931348-B2 Methods of treating elevated plasma cholesterol CETP, LDLR, APOB L3MBTL1 3474/4885ALDH1A1 568/4885KDM4E 4383/4885
US-20230088095-A1 METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL CETP, LDLR, APOB L3MBTL1 3474/4885ALDH1A1 568/4885KDM4E 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.